Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H15NO2 |
Molecular Weight | 169.2209 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OC1CN2CCC1CC2
InChI
InChIKey=WRJPSSPFHGNBMG-UHFFFAOYSA-N
InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10411607Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10411607
Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594
Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate (cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10411607
Curator's Comment: Known to be CNS penetrant in mouse; rats. Human data not available
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4917903
Curator's Comment: Aceclidine was first prepared in 1960
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440 |
17.0 µM [EC50] | ||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440 |
|||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9715440 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Glaunorm Approved UseGlaucoma, in its different clinical forms Launch Date1969 |
PubMed
Title | Date | PubMed |
---|---|---|
[The selectivity of the action of muscarinic agonists in vivo]. | 1994 Mar-Apr |
|
Pharmacological management of night vision disturbances after refractive surgery Results of a randomized clinical trial. | 2005 Sep |
|
Aceclidine and pilocarpine interact differently with muscarinic receptor in isolated rabbit iris muscle. | 2006 Feb 28 |
|
Aceclidine, brimonidine tartrate, and dapiprazole: comparison of miotic effect and tolerability under different lighting conditions. | 2009 Jan |
|
Effectiveness of daily use of brimonidine as antimydriatic agent. | 2009 Oct |
|
Role of cholinergic and cytokine regulation of T cell function in stimulation and inhibition of immune reactions in intoxication by organophosphorus compounds in different doses. | 2009 Sep |
Patents
Sample Use Guides
Instill 2 drops of Glaunorm (2% aceclidine hydrochloride solution) into the conjunctival sac every 8 hours following the doctor's prescription
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10845594
Human eyes were dissected and perfused. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 1 nM to 10 mM of aceclidine, were added to the perfusion medium. Outflow facility increased from baseline facility in eyes treated with aceclidine at lower concentrations (1 nM to 1 uM) but remained unchanged at higher concentrations.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01EB08
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
||
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
||
|
WHO-ATC |
S01EB58
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
||
|
WHO-VATC |
QS01EB08
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
||
|
WHO-VATC |
QS01EB58
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
827-61-2
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
1979
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
SUB05199MIG
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
DTXSID2045658
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
C084650
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
0578K3ELIO
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
657843
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
m9469
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
C81044
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
DB13262
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
758239
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
Aceclidine
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL20835
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
212-574-1
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
4314
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
1367
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY | |||
|
100000087890
Created by
admin on Fri Dec 15 16:35:08 GMT 2023 , Edited by admin on Fri Dec 15 16:35:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)